LIXTE Appoints Bas van der Baan as President and Chief Executive Officer
26 Setembro 2023 - 9:30AM
LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”)
(Nasdaq: LIXT and LIXTW), a clinical stage biotechnology company
developing a novel class of cancer therapy called PP2A inhibitors,
announced that Bas van der Baan has been named as President and
Chief Executive Officer of the Company, and as Vice Chairman of the
Board of Directors, effective as of September 26, 2023. He has been
a member of LIXTE’S Board of Directors since June 2022. Mr. van der
Baan succeeds John S. Kovach, M.D., 87, who founded the Company in
2005 and was named Executive Chairman. Dr. Kovach will continue as
the Company’s Chief Scientific Officer. Both Dr. Kovach and Mr. van
der Baan will continue in their roles as members of the Board of
Directors of LIXTE.
Mr. van der Baan, 51, has more than 20 years of
experience in the biotechnology industry, with a key focus on
oncology and diagnostics. Most recently, he was the Chief Clinical
and Business Development Officer of Agendia, Inc. in Irvine,
California and Amsterdam, Netherlands. In that role, Mr. van der
Baan was instrumental in the initiation and execution of numerous
clinical trials that led to full commercialization and adoption of
precision molecular oncology diagnostics. He initiated the launch
of Agendia’s business operations in the United States and has broad
knowhow in clinical development, both in the United States and in
Europe.
“Bas has extensive expertise managing products
from clinical development to commercialization, and along with his
involvement in establishing partnerships with pharmaceutical
companies, he will be highly valuable to LIXTE in the next phase of
the Company’s development,” said Dr. Kovach. “I look forward to
working closely with Bas in my new role as Executive Chairman, as
we continue to focus on expediting the clinical development of our
promising lead compound, LB-100.”
“During my tenure serving on the Board of
Directors, I have worked with the entire LIXTE team and am
impressed with the progress made with LB-100. I am honored and
delighted to accept this position with LIXTE as the Company
continues its journey through the clinical trial process,” Mr. van
der Baan said. “I look forward to leading LIXTE in its mission to
improve medical outcomes for patients undergoing various
chemotherapies and immunotherapies, and to establishing and
commercializing what we believe to be the significant clinical
potential of LB-100.”
About LIXTE Biotechnology Holdings,
Inc.
LIXTE Biotechnology Holdings, Inc. is a
clinical-stage pharmaceutical company developing a new class of
cancer therapy called PP2A inhibitors. The Company’s innovative
approach enhances the efficacy of both chemotherapy and
immunotherapy, potentially providing new treatment
options for patients. At the core of the Company’s therapy is
LB-100, the Company’s proprietary compound that acts as
an inhibitor of the PP2A phosphatase with a favorable
toxicity profile. LB-100 promotes the production of neoantigens and
cytokines, boosts T-cell proliferation, and disrupts the DNA repair
mechanisms of cancer cells, potentially improving
treatment outcomes. The Company is conducting multiple clinical
trials for solid tumors with unmet medical needs. LIXTE's unique
approach has no known competitors and is covered by a comprehensive
patent portfolio.
Additional information about LIXTE can be
obtained at www.lixte.com and by reviewing the Company's filings
with the United States Securities and Exchange Commission
at https://www.sec.gov.
Forward-Looking Statements
This announcement contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, and Section 21E of the Securities Exchange
Act of 1934. For example, statements regarding the Company's
financial position, business strategy and other plans and
objectives for future operations, and assumptions and predictions
about future activities, including the continuing development of
proprietary compounds, the planning, funding, coordination and
potential results of clinical trials, and the patent and legal
costs to protect and maintain the Company's intellectual property
worldwide, are all forward-looking statements. These statements are
generally accompanied by words such as "intend," anticipate,"
"believe," "estimate," "potential(ly)," "continue," "forecast,"
"predict," "plan," "may," "will," "could," "would," "should,"
"expect" or the negative of such terms or other comparable
terminology. The Company believes that the assumptions and
expectations reflected in such forward-looking statements are
reasonable, based on information available to it on the date
hereof, but the Company cannot provide assurances that these
assumptions and expectations will prove to have been correct or
that the Company will take any action that the Company may
presently be planning. However, these forward-looking statements
are inherently subject to known and unknown risks and
uncertainties. Actual results or experience may differ materially
from those expected or anticipated in the forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, regulatory policies,
available cash, research results, competition from other similar
businesses, and market and general economic factors. This
discussion should be read in conjunction with the Company's filings
with the United States Securities and Exchange Commission
at https://www.sec.gov.
For more information about
LIXTE, Contact:
info@lixte.comGeneral Phone: (631) 830-7092Investor Phone: (888)
289-5533orPondelWilkinson Inc. Investor
Relationspwinvestor@pondel.comRoger Pondel or Laurie Berman: (310)
279-5980
- Lixte Biotechnology Holdings, Inc.
Lixte Biotechnology (NASDAQ:LIXT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Lixte Biotechnology (NASDAQ:LIXT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024